Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

Introduction: The phase 3 DUPLEX trial is evaluating sparsentan, a novel, nonimmunosuppressive, single-molecule dual endothelin angiotensin receptor antagonist, in patients with focal segmental glomerulosclerosis (FSGS). Methods: DUPLEX (NCT03493685) is a global, multicenter, randomized, double-blin...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Howard Trachtman, Jai Radhakrishnan, Michelle N. Rheault, Charles E. Alpers, Jonathan Barratt, Hiddo J.L. Heerspink, Irene L. Noronha, Vlado Perkovic, Brad Rovin, Hernán Trimarchi, Muh Geot Wong, Alex Mercer, Jula Inrig, William Rote, Ed Murphy, Patricia W. Bedard, Sandra Roth, Stewart Bieler, Radko Komers
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2024-04-01
Saila:	Kidney International Reports
Gaiak:	dual endothelin angiotensin receptor antagonist focal segmental glomerulosclerosis pediatric race randomized controlled clinical trial sparsentan
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2468024924000421
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!